- Home
- PCSA vs ARTW Comparison
PCSA vs ARTW Comparison
Compare PCSA & ARTW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCSA
- ARTW
- Stock Information
- Founded
- PCSA 2011
- ARTW 1956
- Country
- PCSA United States
- ARTW United States
- Employees
- PCSA N/A
- ARTW N/A
- Industry
- PCSA Biotechnology: Pharmaceutical Preparations
- ARTW Industrial Machinery/Components
- Sector
- PCSA Health Care
- ARTW Industrials
- Exchange
- PCSA Nasdaq
- ARTW Nasdaq
- Market Cap
- PCSA 12.0M
- ARTW 12.5M
- IPO Year
- PCSA N/A
- ARTW N/A
- Fundamental
- Price
- PCSA $0.32
- ARTW $2.50
- Analyst Decision
- PCSA Strong Buy
- ARTW
- Analyst Count
- PCSA 1
- ARTW 0
- Target Price
- PCSA $1.00
- ARTW N/A
- AVG Volume (30 Days)
- PCSA 24.6M
- ARTW 60.0K
- Earning Date
- PCSA 11-06-2025
- ARTW 10-07-2025
- Dividend Yield
- PCSA N/A
- ARTW N/A
- EPS Growth
- PCSA N/A
- ARTW N/A
- EPS
- PCSA N/A
- ARTW 0.49
- Revenue
- PCSA N/A
- ARTW $24,079,949.00
- Revenue This Year
- PCSA N/A
- ARTW N/A
- Revenue Next Year
- PCSA N/A
- ARTW N/A
- P/E Ratio
- PCSA N/A
- ARTW $6.61
- Revenue Growth
- PCSA N/A
- ARTW N/A
- 52 Week Low
- PCSA $0.15
- ARTW $1.43
- 52 Week High
- PCSA $1.50
- ARTW $4.71
- Technical
- Relative Strength Index (RSI)
- PCSA 52.55
- ARTW 42.61
- Support Level
- PCSA $0.29
- ARTW $2.30
- Resistance Level
- PCSA $0.34
- ARTW $2.67
- Average True Range (ATR)
- PCSA 0.05
- ARTW 0.26
- MACD
- PCSA -0.01
- ARTW -0.02
- Stochastic Oscillator
- PCSA 27.62
- ARTW 22.02
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
About ARTW Art's-Way Manufacturing Co. Inc.
Art's-Way Manufacturing Co Inc is a manufacturer of agricultural equipment. It has two reportable segments: Agricultural Products, and Modular Buildings. The Agricultural Products segment fabricates and sells farming products as well as related equipment and replacement parts for these products in the United States and world wide. Its Modular Buildings segment manufactures and installs modular buildings for animal containment and various laboratory uses. It derives revenues from the Agricultural Products segment.